Why the study?
Acute massive PE requiring ECMO in children with protein S deficiency presents a therapeutic dilemma of reconciling the inherent hypercoagulable state and obligatory ECMO anticoagulation with the high bleeding risk following thrombolytic therapy.
Case Report (n=1)
No
Demonstrates that an individualized low-dose unfractionated heparin protocol guided by the 2025 PEACE consensus can safely balance circuit thromboprophylaxis and severe bleeding risk in a pediatric VA-ECMO patient with protein S deficiency, prior intracerebral hemorrhage, and recent thrombolysis for massive pulmonary embolism.
Answers are grounded in this paper and cite their sources.
May support individualized low-dose heparin in complex pediatric VA-ECMO; hypothesis-generating and requires prospective validation.
Introduction Protein S deficiency is a predominant form of hereditary thrombophilia in Asian populations. Pediatric venous thromboembolism (VTE) is exceedingly rare, with an incidence of only 0.2%–0.6%, and acute massive pulmonary embolism (PE) requiring extracorporeal membrane oxygenation (ECMO) support in children with thrombophilia presents exceptional clinical challenges. The core therapeutic dilemma lies in reconciling the hypercoagulable state inherent to protein S deficiency with the high bleeding risk following thrombolytic therapy, compounded by the obligatory anticoagulation requirement during ECMO. This case report describes the nursing management of a pediatric patient with protein S deficiency and acute PE who successfully underwent ECMO-supported interventional treatment under high bleeding risk. Outcome The patient was successfully weaned from ECMO after 98 h of support, extubated on day 6, and discharged in stable condition after 30 days of hospitalization. At 6-month follow-up, no thrombus recurrence was observed, and the patient had fully resumed normal life and academic activities. Conclusion This case demonstrates that an individualized low-dose heparin anticoagulation strategy, guided by the PEACE consensus and supported by meticulous monitoring, can effectively balance the competing risks of thrombosis and hemorrhage in pediatric ECMO patients with underlying thrombophilia and recent thrombolysis. Notably, as a single case report, this finding cannot be broadly generalized to all pediatric ECMO patients with thrombophilia. Instead, this case provides a potential framework for individualized anticoagulation and nursing management that requires further validation in larger pediatric cohorts. The nursing experience provides a practical reference for managing similar complex cases in pediatric critical care.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) conducted a case report in Protein S deficiency and acute massive pulmonary embolism requiring VA-ECMO support (n=1). Individualized low-dose unfractionated heparin (UFH) anticoagulation during VA-ECMO and catheter-based pulmonary artery intervention was evaluated on Successful ECMO weaning, survival to hospital discharge, and freedom from thrombus recurrence or major hemorrhage.
Synapse has enriched 10 related papers. Consider them for comparative context: